Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. | ITV National News
Continue reading this article about Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
by ITV News
NHS Forums - For daily discussion by NHS Staff.
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. | ITV National News
Continue reading this article about Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
by ITV News
NHS Forums - For daily discussion by NHS Staff.